{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T06:55:38Z","timestamp":1776840938497,"version":"3.51.2"},"reference-count":118,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ijrobp.2022.06.084","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T11:41:05Z","timestamp":1656934865000},"page":"780-791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Critical Review of the Role of Local Therapy for Oligometastatic Gastrointestinal Cancer"],"prefix":"10.1016","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7590-558X","authenticated-orcid":false,"given":"Krishan R.","family":"Jethwa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaohui","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher L.","family":"Hallemeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2022.06.084_bib0001","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0002","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: A European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0003","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/00000658-200206000-00002","article-title":"Trends in long-term survival following liver resection for hepatic colorectal metastases","volume":"235","author":"Choti","year":"2002","journal-title":"Ann Surg"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0004","first-page":"283","article-title":"Survival after liver resection in metastatic colorectal cancer: Review and meta-analysis of prognostic factors","volume":"4","author":"Kanas","year":"2012","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0005","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/01.sla.0000160703.75808.7d","article-title":"Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases","volume":"241","author":"Pawlik","year":"2005","journal-title":"Ann Surg"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0006","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0007","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): A randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0008","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0009","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0010","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","article-title":"The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer","volume":"600","author":"Janjigian","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0011","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0012","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/0284186X.2016.1240880","article-title":"Supraclavicular node disease is not an independent prognostic factor for survival of esophageal cancer patients treated with definitive chemoradiation","volume":"56","author":"Jeene","year":"2017","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0013","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1093\/oxfordjournals.jjco.a023238","article-title":"Phase II study of chemoradiotherapy for advanced squamous cell carcinoma of the thoracic esophagus: Nine Japanese institutions trial","volume":"26","author":"Ishida","year":"1996","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0014","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/jjco\/hyh107","article-title":"Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: A Japan Esophageal Oncology Group (JEOG)\/Japan Clinical Oncology Group trial (JCOG9516)","volume":"34","author":"Ishida","year":"2004","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0015","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00423-018-1722-x","article-title":"Supraclavicular and celiac metastases in squamous cell carcinoma of the middle thoracic esophagus","volume":"403","author":"Okamura","year":"2018","journal-title":"Langenbecks Arch Surg"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0016","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1245\/s10434-019-08175-0","article-title":"Clinicopathologic characteristics of oligometastases from esophageal cancer and long-term outcomes of resection","volume":"27","author":"Ohkura","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0017","doi-asserted-by":"crossref","first-page":"11259","DOI":"10.1038\/s41598-020-68160-6","article-title":"Development and validation of a nomogram prognostic model for esophageal cancer patients with oligometastases","volume":"10","author":"Li","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0018","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s00268-012-1830-7","article-title":"Pattern of postoperative recurrence and hepatic and\/or pulmonary resection for liver and\/or lung metastases from esophageal carcinoma","volume":"37","author":"Ichida","year":"2013","journal-title":"World J Surg"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0019","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.radonc.2020.09.042","article-title":"Radical radiotherapy for metachronous oligometastasis after initial treatment of esophageal cancer","volume":"154","author":"Li","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0020","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.21873\/anticanres.14164","article-title":"Stereotactic body radiotherapy for pulmonary oligometastases from esophageal cancer: Results and prognostic factors","volume":"40","author":"Yamamoto","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0021","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ijrobp.2020.05.003","article-title":"Phase 2 study of stereotactic body radiation therapy for patients with oligometastatic esophageal squamous cell carcinoma","volume":"108","author":"Liu","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0022","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/annonc\/mdn026","article-title":"Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases","volume":"19","author":"Cheon","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0023","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/jjco\/hyh120","article-title":"Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study","volume":"34","author":"Yoshida","year":"2004","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0024","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1470-2045(15)00553-7","article-title":"Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): A phase 3, randomised controlled trial","volume":"17","author":"Fujitani","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0025","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamaoncol.2017.0515","article-title":"Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: The AIO-FLOT3 trial","volume":"3","author":"Al-Batran","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0026","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1186\/s12885-017-3918-9","volume":"17","author":"Al-Batran","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0027","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000475550","article-title":"101 long-term survivors who had metastatic gastroesophageal cancer and received local consolidative therapy","volume":"93","author":"Mizrak Kaya","year":"2017","journal-title":"Oncology"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0028","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3346\/jkms.2009.24.3.488","article-title":"Stereotactic body radiotherapy for isolated para-aortic lymph node recurrence after curative resection in gastric cancer","volume":"24","author":"Kim","year":"2009","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0029","unstructured":"ClinicalTrials.gov. Testing the addition of radiotherapy to the usual treatment (chemotherapy) for patients with esophageal and gastric cancer that has spread to a limited number of other places in the body. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04248452. Accessed September 17, 2022."},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0030","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"issue":"4_suppl","key":"10.1016\/j.ijrobp.2022.06.084_bib0031","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1200\/JCO.2022.40.4_suppl.379","article-title":"Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA","volume":"40","author":"Abou-Alfa","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0032","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00534-010-0330-0","article-title":"Complications of the treatment of endoscopic biliary strictures developing after liver transplantation","volume":"18","author":"Kobayashi","year":"2011","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0033","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.surg.2014.07.024","article-title":"Clinicopathological factors and long-term outcome comparing between lung and peritoneal metastasectomy after hepatectomy for hepatocellular carcinoma in a tertiary institution","volume":"157","author":"Kow","year":"2015","journal-title":"Surgery"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0034","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1007\/s00268-016-3580-4","article-title":"Prognostic analysis of surgical resection for pulmonary metastasis from hepatocellular carcinoma","volume":"40","author":"Takahashi","year":"2016","journal-title":"World J Surg"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/JHC.S290197","article-title":"Efficacy of local therapy for oligometastatic hepatocellular carcinoma: A propensity score matched analysis","volume":"8","author":"Kim","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0036","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/jjco\/hyac028","article-title":"Stereotactic ablative radiotherapy for pulmonary oligometastases from primary hepatocellular carcinoma: A multicenter and retrospective analysis (KROG 17-08)","volume":"52","author":"Jo","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0037","unstructured":"ClinicalTrials.gov. Stereotactic ablative radiotherapy for oligometastatic hepatocellular carcinoma. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05173610. Accessed March 24, 2022."},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0038","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"issue":"4_suppl","key":"10.1016\/j.ijrobp.2022.06.084_bib0039","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1200\/JCO.2022.40.4_suppl.378","article-title":"A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1","volume":"40","author":"Oh","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0040","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1245\/s10434-020-08207-0","article-title":"Proposed definition for oligometastatic recurrence in biliary tract cancer based on results of locoregional treatment: A propensity-score-stratified analysis","volume":"27","author":"Morino","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0041","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1007\/s00432-020-03285-9","article-title":"Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: Single-institution analysis of outcome and toxicity","volume":"146","author":"Franzese","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0042","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0043","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2020.101607","article-title":"Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO group","volume":"45","author":"Breton","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0045","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20190627","article-title":"Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question","volume":"93","author":"Scorsetti","year":"2020","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0046","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/MPA.0000000000001822","article-title":"Liver metastasis-directed ablative radiotherapy in pancreatic cancer offers prolonged time off systemic therapy in selected patients: Data from a multi-institutional retrospective study","volume":"50","author":"Lee","year":"2021","journal-title":"Pancreas"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0047","unstructured":"ClinicalTrials.gov. Chemotherapy and surgical resection in patients with hepatic oligometastatic adenocarcinoma of the pancreas (HOLIPANC)."},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0048","unstructured":"ClinicalTrials.gov. Standard of care chemotherapy with or without stereotactic body radiation therapy for the treatment of oligometastatic pancreatic cancer. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04975516 Accessed March 24, 2022."},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0049","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177)Lu-Dotatate plus long-acting octreotide versus highdose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): Final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0050","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","article-title":"ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0051","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00261-004-0258-4","article-title":"Radiofrequency ablation of neuroendocrine liver metastases: The Middlesex experience","volume":"30","author":"Gillams","year":"2005","journal-title":"Abdom Imaging"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0052","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/MPA.0000000000000030","article-title":"Comparison of transarterial liver-directed therapies for low-grade metastatic neuroendocrine tumors in a single institution","volume":"43","author":"Engelman","year":"2014","journal-title":"Pancreas"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0053","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.jvir.2017.05.011","article-title":"Long-term hepatotoxicity of yttrium-90 radioembolization as treatment of metastatic neuroendocrine tumor to the liver","volume":"28","author":"Su","year":"2017","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0054","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000336941","article-title":"Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases from well-differentiated midgut endocrine tumors: A prospective randomized study","volume":"96","author":"Maire","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0055","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s12020-013-0130-9","article-title":"Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors","volume":"47","author":"Fiore","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0056","unstructured":"ClinicalTrials.gov. Randomized embolization trial for neuroendocrine tumor metastases to the liver. Available at: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02724540. Accessed March 24, 2022."},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0057","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000514914","article-title":"Stereotactic ablative radiotherapy for the management of liver metastases from neuroendocrine neoplasms: A preliminary study","volume":"112","author":"Hudson","year":"2022","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0058","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and treatment of metastatic colorectal cancer: A review","volume":"325","author":"Biller","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0059","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0140-6736(10)60837-9","article-title":"Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): An international, prospective, randomised, non-inferiority phase 3 trial","volume":"376","author":"Vaidya","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0060","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1001\/jama.2017.7105","article-title":"Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: A randomized clinical trial","volume":"317","author":"Venook","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0061","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1200\/JCO.20.00174","article-title":"Bevacizumab plus mFOLFOX6 versus mFOLFOX6 alone as first-line treatment for RAS mutant unresectable colorectal liver-limited metastases: The BECOME randomized controlled trial","volume":"38","author":"Tang","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0062","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1200\/JCO.2012.42.2592","article-title":"Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab","volume":"30","author":"Tejpar","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0063","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1200\/JCO.2016.71.4394","article-title":"Non-V600) BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer","volume":"35","author":"Jones","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0064","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0065","unstructured":"ClinicalTrials.gov. Encorafenib, binimetinib and cetuximab in subjects with previously untreated BRAF-mutant colorectal cancer (ANCHOR-CRC). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03693170. Accessed March 24, 2022."},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0066","unstructured":"ClinicalTrials.gov. A study of encorafenib plus cetuximab with or without chemotherapy in people with previously untreated metastatic colorectal cancer. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04607421. Accessed March 24, 2022."},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0067","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0068","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1001\/archsurg.141.5.460","article-title":"Solitary colorectal liver metastasis: Resection determines outcome","volume":"141","author":"Aloia","year":"2006","journal-title":"Arch Surg"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0069","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.amjsurg.2008.04.013","article-title":"Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases","volume":"197","author":"Hur","year":"2009","journal-title":"Am J Surg"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0070","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/MCG.0b013e318064e752","article-title":"Clinical outcomes of hepatic resection and radiofrequency ablation in patients with solitary colorectal liver metastasis","volume":"42","author":"Lee","year":"2008","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0071","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S1470-2045(13)70447-9","article-title":"Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): Long-term results of a randomised, controlled, phase 3 trial","volume":"14","author":"Nordlinger","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0072","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.athoracsur.2009.03.034","article-title":"Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases","volume":"87","author":"Onaitis","year":"2009","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0073","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1634\/theoncologist.2017-0456","article-title":"A curative-intent trimodality approach for isolated abdominal nodal metastases in metastatic colorectal cancer: Update of a single-institutional experience","volume":"23","author":"Johnson","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0074","first-page":"e489","article-title":"Pulmonary metastasectomy in colorectal cancer: The PulMiCC randomised controlled trial","volume":"107","author":"Treasure","year":"2020","journal-title":"Br J Surg"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0075","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): A multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Qu\u00e9net","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0076","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1245\/s10434-010-1459-4","article-title":"Liver resection for colorectal metastases in presence of extrahepatic disease: results from an international multi-institutional analysis","volume":"18","author":"Pulitan\u00f2","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0077","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.ejca.2011.10.034","article-title":"Hepatectomy and resection of concomitant extrahepatic disease for colorectal liver metastases\u2014a systematic review","volume":"48","author":"Chua","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0078","doi-asserted-by":"crossref","first-page":"djx015","DOI":"10.1093\/jnci\/djx015","article-title":"Local treatment of unresectable colorectal liver metastases: Results of a randomized phase II trial","volume":"109","author":"Ruers","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0079","unstructured":"ClinicalTrials.gov. COLLISION trial - colorectal liver metastases: Surgery vs thermal ablation (COLLISION). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03088150. Accessed March 24, 2022."},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0080","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/annonc\/mdv037","article-title":"Radiofrequency ablation is a valid treatment option for lung metastases: Experience in 566 patients with 1037 metastases","volume":"26","author":"de Ba\u00e8re","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0081","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.radonc.2018.06.035","article-title":"Stereotactic body radiotherapy for colorectal cancer liver metastases: A systematic review","volume":"129","author":"Petrelli","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0082","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s12885-018-4191-2","article-title":"The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): Patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases","volume":"18","author":"Andratschke","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0083","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.radonc.2021.10.023","article-title":"A multicenter LArge retrospectIve daTabase on the personalization of stereotactic ABlative radiotherapy use in lung metastases from colon-rectal cancer: The LaIT-SABR study","volume":"166","author":"Nicosia","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0084","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.radonc.2020.02.008","article-title":"Association of tumor genomic factors and efficacy for metastasis-directed stereotactic body radiotherapy for oligometastatic colorectal cancer","volume":"146","author":"Jethwa","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0085","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13014-015-0369-9","article-title":"Stereotactic radiation therapy for liver metastases: factors affecting local control and survival","volume":"10","author":"Andratschke","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0086","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.radonc.2021.12.018","article-title":"An analysis of a large multi-institutional database reveals important associations between treatment parameters and clinical outcomes for stereotactic body radiotherapy (SBRT) of oligometastatic colorectal cancer","volume":"167","author":"Sheikh","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0087","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ijrobp.2017.07.030","article-title":"Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer","volume":"99","author":"Joo","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0088","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx031","article-title":"Phase II study of proton-based stereotactic body radiation therapy for liver metastases: Importance of tumor genotype","volume":"109","author":"Hong","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0089","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/bjs.9870","article-title":"Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases","volume":"102","author":"Brudvik","year":"2015","journal-title":"Br J Surg"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0090","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2018.0996","article-title":"Association of braf mutations with survival and recurrence in surgically treated patients with metastatic colorectal liver cancer","volume":"153","author":"Margonis","year":"2018","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0091","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/02656736.2018.1556818","article-title":"The value of KRAS gene status in predicting local tumor progression of colorectal liver metastases following radiofrequency ablation","volume":"36","author":"Jiang","year":"2019","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0092","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1007\/s00330-020-07253-2","article-title":"Transarterial chemoembolization of colorectal cancer liver metastasis: Improved tumor response by DSM-TACE versus conventional TACE, a prospective, randomized, single-center trial","volume":"31","author":"Vogl","year":"2021","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0093","first-page":"1387","article-title":"Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: Final results of a phase III study","volume":"32","author":"Fiorentini","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0094","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1002\/cncr.29534","article-title":"Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis","volume":"121","author":"Martin","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0095","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1200\/JCO.2015.66.1181","article-title":"SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer","volume":"34","author":"van Hazel","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0096","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S1470-2045(17)30457-6","article-title":"First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): A combined analysis of three multicentre, randomised, phase 3 trials","volume":"18","author":"Wasan","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0097","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1200\/JCO.21.01839","article-title":"Radioembolization with chemotherapy for colorectal liver metastases: A randomized, open-label, international, multicenter, phase III trial","volume":"39","author":"Mulcahy","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0098","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.suronc.2015.06.014","article-title":"Systematic review and meta-analysis of hepatic arterial infusion chemotherapy as bridging therapy for colorectal liver metastases","volume":"24","author":"Chan","year":"2015","journal-title":"Surg Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0099","first-page":"1499","article-title":"Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: Surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy\u2014an intergroup study","volume":"20","author":"Kemeny","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0100","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJM199912303412702","article-title":"Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer","volume":"341","author":"Kemeny","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0101","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1200\/JCO.2008.20.1301","article-title":"Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma","volume":"27","author":"Kemeny","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0102","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1200\/JCO.2005.03.8166","article-title":"Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: A randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481)","volume":"24","author":"Kemeny","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0103","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/annonc\/mdv548","article-title":"Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV","volume":"27","author":"L\u00e9vi","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0104","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/jso.24898","article-title":"Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential","volume":"117","author":"Pak","year":"2018","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0105","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/SLA.0000000000000614","article-title":"Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: Conversion to resection and long-term outcomes","volume":"261","author":"D\u02bcAngelica","year":"2015","journal-title":"Ann Surg"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0106","doi-asserted-by":"crossref","unstructured":"Schiff JP, Chin RI, Roy A, et al. Oligometastatic rectal adenocarcinoma treated with short-course radiotherapy and chemotherapy with nonoperative intent of the primary for locoregional complete responders [e-pub ahead of print]. Pract Radiat Oncol. Available at: https:\/\/doi.org\/10.1016\/j.prro.2022.04.008. Accessed April 21, 2022.","DOI":"10.1016\/j.prro.2022.04.008"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0107","doi-asserted-by":"crossref","first-page":"990","DOI":"10.21037\/jgo.2017.09.02","article-title":"Short course radiation as a component of definitive multidisciplinary treatment for select patients with metastatic rectal adenocarcinoma","volume":"8","author":"Holliday","year":"2017","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0108","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.19.03266","article-title":"International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAAct","volume":"38","author":"Rao","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0109","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijrobp.2018.04.076","article-title":"Extended-field chemoradiation therapy for definitive treatment of anal canal squamous cell carcinoma involving the para-aortic lymph nodes","volume":"102","author":"Holliday","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0110","doi-asserted-by":"crossref","first-page":"11133","DOI":"10.18632\/oncotarget.2563","article-title":"The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal","volume":"5","author":"Eng","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0111","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/DCR.0000000000000827","article-title":"Multimodal therapy of squamous cell carcinoma of the anus with distant metastasis: A single-institution experience","volume":"60","author":"Evesque","year":"2017","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0112","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.ejso.2017.09.006","article-title":"Long term outcome after resection of liver metastases from squamous cell carcinoma","volume":"43","author":"Omichi","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0113","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1245\/s10434-007-9467-8","article-title":"Liver-directed surgery for metastatic squamous cell carcinoma to the liver: Results of a multi-center analysis","volume":"14","author":"Pawlik","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0114","first-page":"65","article-title":"Definitive chemoradiation in oligometastatic squamous cell carcinoma of the anal canal","volume":"7","author":"Rogers","year":"2014","journal-title":"Gastrointest Cancer Res"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0115","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/jso.25320","article-title":"Multimodality treatment of oligometastatic anal squamous cell carcinoma: A case series and literature review","volume":"119","author":"Sclafani","year":"2019","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0116","unstructured":"ClinicalTrials.gov. Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer (SABR-COMET-3). Available at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03862911. Accessed March 24, 2022."},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0117","unstructured":"ClinicalTrials.gov. Stereotactic Ablative Radiotherapy for Comprehensive Treatment of 4-10 Oligometastatic Tumors (SABR-COMET 10). Available at https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03721341. Accessed March 24, 2022."},{"key":"10.1016\/j.ijrobp.2022.06.084_bib0118","unstructured":"ClinicalTrials.gov. Systemic Therapy With or Without Local Consolidative Therapy in Treating Patients With Oligometastatic Solid Tumor. Available at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03599765. Accessed March 24, 2022."}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301622006617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301622006617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:59:07Z","timestamp":1759744747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301622006617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":118,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0360301622006617"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2022.06.084","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Critical Review of the Role of Local Therapy for Oligometastatic Gastrointestinal Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2022.06.084","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}